摘要:
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
摘要翻译:本发明提供结合蛋白,包括抗体,抗体衍生物和抗体片段,并特异性结合CD154(CD40L)蛋白。 本发明因此提供了一个嵌合的,人源化或完全的人抗体,抗体衍生物或抗体片段在表位做特异性结合到其上的人源化Fab片段包括雅丁于SEQ ID NO的可变重链序列:1和包含可变轻链序列 根据SEQ ID NO:2特异性结合。 CD154结合本发明的蛋白可以引起相对于第二抗CD154抗体效应子功能降低。 本发明的CD154结合蛋白可用于诊断和治疗方法,:例如在治疗和预防疾病,包括涉及thosethat不希望的免疫应答通过做了CD154-CD40相互作用介导有用的。
摘要:
A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
摘要翻译:1.一种血清白蛋白结合抗体或其片段,其包含具有SEQ ID NO:1或SEQ ID NO:2中给出的序列的重链可变结构域和/或包含具有SEQ ID NO:3中给出的序列的轻链可变区或 SEQ ID NO:4,特别包括具有SEQ ID NO:1和SEQ ID NO:3中给出的序列的重链可变结构域和轻链可变结构域或重链可变结构域和具有 SEQ ID NO:2和SEQ ID NO:4中给出的序列。 本公开还延伸到编码抗体或片段的多核苷酸,包含其的载体和能够表达多核苷酸的宿主细胞。 本公开还包括药物组合物,其包含使用其中任何一种的抗体或片段和治疗剂。
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要:
A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest which are a VH/VL pair, wherein the two single domain antibodies are linked by a disulfide bond. Also provided are particular dual specificity antibody fusion proteins and other antibody fragments which are stabilised by a disulfide bond.
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要:
The present invention provides a recombinant antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a C H1 constant region fragment located between a first and second variable domain, and a third variable domain linked directly or indirectly to the first or second variable domain, with the proviso that the heavy chain only contains one C H1 and only contains three variable domains, and a light chain comprising at least a C L domain located between a first and second variable domain, and a third variable domain linked directly or indirectly to the first or second variable domain, with the proviso that the light chain only contains one C L domain and only contains three variable domains, and wherein said heavy and light chains are aligned to provide a first binding site formed by the first variable domains in the light and heavy chain, a second binding site formed by the second variable domains in the light and heavy chain, and a third binding site formed by the third variable domains in the light and heavy chain.
摘要:
The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks.
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.